R&D | Cutting-edge science and innovative research

News

Novo Nordisk's dropping share price spells the end for CEO

Novo Nordisk's chief executive Lars Fruergaard Jørgensen is stepping down by "mutual agreement" with the company's board.

News

Pathos AI's big $365m Series D, and other bio financings

Our round-up of recent biotech financings includes rounds for Pathos AI, Stylus Medicine, Haya Therapeutics, Therini Bio and Tiltbio.

News

Datavant, Aetion merger creates real-world data force

Datavant and Aetion merger promises "faster, more actionable" real-world data insights across pharma's clinical and commercial lifecycle.

R&D

Jonah Comstock interviews Dr Dhaval Shah at AAPS

Modelling biologics: Challenges and opportunities, with Dr D...

From AAPS 2025, an interview with Dr Dhaval Shah, professor of pharmaceutical sciences at the University of Buffalo and former Pfizer researcher.

News

Sanofi pledges a $20 billion investment programme in the US

Sanofi is the latest European pharma group to promise a big capital investment programme on manufacturing and R&D in the US.

News

Novo makes fresh obesity play with $2.2bn Septerna deal

A new licensing deal with Septerna suggests Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity.

News

GSK pays $1.2bn for liver drug as it culls TIGIT programme

GSK decided to abandon a TIGIT-targeted drug for cancer this week, then hatched a plan to replace it with a candidate for liver disease MASH.

R&D

Q1 Clinical trials round-up: Jan-Mar 2025

The first quarter of 2025 saw a wave of significant advancements in clinical research across oncology, neurology, dermatology, respiratory, and rare diseases.

Debates & Insights

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

Sponsored

Synthetic control arms in clinical trials: Making it happen

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/live.png

Webinars

Sponsored

How synthetic control arms are changing clinical trials

Clinical trials are involved, expensive, and have been done largely the same way for decades but with today’s technology all that can change.

News

Novo Nordisk's dropping share price spells the end for CEO

Novo Nordisk's chief executive Lars Fruergaard Jørgensen is stepping down by "mutual agreement" with the company's board.

News

Pathos AI's big $365m Series D, and other bio financings

Our round-up of recent biotech financings includes rounds for Pathos AI, Stylus Medicine, Haya Therapeutics, Therini Bio and Tiltbio.

Press Releases

Views & Analysis

Touring Chiesi's vision for the future at the new Biotech Ce...

Following an invite to fly into Parma, Italy to witness first-hand the press launch of the considerable structure – black-painted and as yet under construction, gigantic cranes and all – th

News

Vir awarded $1 billion multi-year BARDA influenza contract

The US Government’s Biomedical Advanced Research and Development Authority (BARDA) has made an

Views & Analysis

R&D

Modelling biologics: Challenges and opportunities, with Dr D...

From AAPS 2025, an interview with Dr Dhaval Shah, professor of pharmaceutical sciences at the University of Buffalo and former Pfizer researcher.

R&D

Multilateral benefit sharing mechanism for digital sequence ...

Since December 2022, and COP decision 15/9, members of the Convention on Biolog

R&D

FT US Pharma and Biotech Summit 2025: Live coverage

We’re back this year, this time virtually attending the FT US Pharma and Biotech Summit in New York City, a one-day event where top pharma execs will come together to discuss the major tren

Deep Dive

R&D

R&D Contraceptive pills condoms and intrauterine device

Research and Development

R&D

Deep Dive: Research and Development 2025

Every breakthrough in medicine, every new treatment that changes lives, starts with research.

R&D

Breaking through financial barriers to clinical trials: How ...

R&D

Sponsored

Exploring the future: Opportunities and challenges in cell a...

Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.

R&D

Sponsored

Beyond clinical: Boosting recruitment and retention with SDO...

The success of clinical trials hinges on a complex array of factors, many of which extend beyond traditional clinical care.

R&D

evolution of clinical research in the UK

Sponsored

The evolution of clinical research: Embracing new delivery m...

The UK is welcoming a new era of clinical trial delivery, evolving beyond the traditional site-centric approach to also embrace remote, decentralised, virtual, and hybrid trials and enablin

Podcasts

R&D

pharmaphorum podcast Episode 174a - Tomasz Kostrzewski, CN Bio

Driving the drug discovery pipeline: The value of organ-on-a...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Tomasz Kostrzewski, CSO at CN Bio, about single organ-on-a-chip technology.

R&D

pharmaphorum podcast Episode 173a - Sonia A. Veluchamy, Celegence

Intelligent regulatory compliance and improved patient outco...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Sonia A. Veluchamy, CEO and co-founder of Celegence.

R&D

pharmaphorum podcast Episode 171a - Dean Alms

Safeguarding the pharmaceutical supply chain

Video

R&D

Modelling biologics: Challenges and opportunities, with Dr D...

From AAPS 2025, an interview with Dr Dhaval Shah, professor of pharmaceutical sciences at the University of Buffalo and former Pfizer researcher.

Digital

Eric Luellen and Jonah Comstock interview at AAPS

AI-powered drug discovery is outpacing regulators, with Eric...

During the AAPS National Biotech Conference 2025, pharmaphorum’s Jonah Comstock sat down with Eric Luellen, the founder and CTIO of Turing Biosciences

R&D

Supercharging clinical development with RWE – with Recursion...

Greater availability of real-world data and real-world evidence is rapidly changing the landscape of drug development.

White Papers

R&D

Life Sciences Industry Report - Part 7 cover image

Life Sciences Industry Report - Biologics and Generics

The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.

R&D

Life Sciences Industry Report - Rare Disease Space

There are some 7,000 known rare diseases in the world, yet, multiple challenges and unmet needs remain when it comes to therapies for these diseases.

R&D

Life Sciences Industry Report 2025 pt2 cover

Life Sciences Industry Report 2025 - GLP-1S: Applicability i...

The pharmaceutical landscape in 2024 was undeniably shaped by the remarkable rise of GLP-1 receptor agonists.

Event

R&D

FT US Pharma and Biotech Summit 2025: Live coverage

We’re back this year, this time virtually attending the FT US Pharma and Biotech Summit in New York City, a one-day event where top pharma execs will come together to discuss the major tren

R&D